Safety, Tolerability and Pharmacokinetics of Recombinant Anti-epidermal Growth Factor Receptor(EGFR) Monoclonal Antibody in Patients With Metastatic Colorectal Cancer
The purpose of this study is to determine whether SCT200 is safe and tolerant in the treatment of metastatic colorectal cancer
Metastatic Colorectal Cancer
BIOLOGICAL: Recombinant full human Anti-EGFR Monoclonal Antibody
Number of participants with SCT200-related adverse events, up to 105 days
Area Under the plasma concentration versus time curve (AUC) of SCT200, prior to the initial dose and 0,0.5,1,2,4,8,24,48 hours,4,7,14,21days post- first dose
Time to Disease Progression (TTP) of SCT200, up to 105 days
The purpose of this study is to determine whether SCT200 is safe and tolerant in the treatment of metastatic colorectal cancer